| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, Florida
Conditional expression systems for 4-repeat wild-type (WT) tau or the corresponding mutants V337M and R406W were established in human neuroglioma H4 cells to study the effect of tau mutations on the physicochemical properties of tau, and to develop a cellular model for the formation of filamentous tau characteristic of frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) and Alzheimer’s disease. Upon induction tau expression increased, reaching maximal levels at 5 to 7 days. WT tau was phosphorylated at amino acids T181, S202/T205, T231, and S396/S404. The R406W mutation decreased tau phosphorylation at each of these sites as did the V337M mutation except for S396/S404 sites that increased. Most tau in postnuclear cell lysates was recovered in the supernatant fraction after centrifugation at 200,000 x g. The amount of tau in the pellet fraction increased more in mutant transfectants compared to WT when the induction was extended beyond 5 days. This particulate tau could be partially extracted with salt, Triton X-100, or sarkosyl. Of the transfectants, R406W had the highest proportion of sarkosyl-insoluble tau by day 7. This insoluble fraction was thioflavin S-positive and contained 15- to 5-nm-wide filaments with tau immunoreactivities. The R406W filaments were more abundant than those detected in similar preparations from WT or V337M transfectants. At the light microscopy level, most tau was found with microtubules, or diffusely distributed in the cytoplasm, but none of this appeared thioflavin S-positive. The results suggest that conditional tau transfectants are in a pretangle stage making them an attractive model system for studying intracellular tangle accumulation and for testing potential therapeutic agents as inhibitors for tau aggregation.
This article has been cited by other articles:
 |
|
 |
|
  M. S. Wolfe Tau Mutations in Neurodegenerative Diseases J. Biol. Chem., March 6, 2009; 284(10): 6021 - 6025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Carrettiero, I. Hernandez, P. Neveu, T. Papagiannakopoulos, and K. S. Kosik The Cochaperone BAG2 Sweeps Paired Helical Filament- Insoluble Tau from the Microtubule J. Neurosci., February 18, 2009; 29(7): 2151 - 2161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Chun and G. V. W. Johnson Activation of Glycogen Synthase Kinase 3beta Promotes the Intermolecular Association of Tau: THE USE OF FLUORESCENCE RESONANCE ENERGY TRANSFER MICROSCOPY J. Biol. Chem., August 10, 2007; 282(32): 23410 - 23417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Bandyopadhyay, G. Li, H. Yin, and J. Kuret Tau Aggregation and Toxicity in a Cell Culture Model of Tauopathy J. Biol. Chem., June 1, 2007; 282(22): 16454 - 16464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ding, T. A. Matthews, and G. V. W. Johnson Site-specific Phosphorylation and Caspase Cleavage Differentially Impact Tau-Microtubule Interactions and Tau Aggregation J. Biol. Chem., July 14, 2006; 281(28): 19107 - 19114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Khlistunova, J. Biernat, Y. Wang, M. Pickhardt, M. von Bergen, Z. Gazova, E. Mandelkow, and E.-M. Mandelkow Inducible Expression of Tau Repeat Domain in Cell Models of Tauopathy: AGGREGATION IS TOXIC TO CELLS BUT CAN BE REVERSED BY INHIBITOR DRUGS J. Biol. Chem., January 13, 2006; 281(2): 1205 - 1214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Sakaue, T. Saito, Y. Sato, A. Asada, K. Ishiguro, M. Hasegawa, and S.-i. Hisanaga Phosphorylation of FTDP-17 Mutant tau by Cyclin-dependent Kinase 5 Complexed with p35, p25, or p39 J. Biol. Chem., September 9, 2005; 280(36): 31522 - 31529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Seki, N. Adachi, Y. Ono, H. Mochizuki, K. Hiramoto, T. Amano, H. Matsubayashi, M. Matsumoto, H. Kawakami, N. Saito, et al. Mutant Protein Kinase C{gamma} Found in Spinocerebellar Ataxia Type 14 Is Susceptible to Aggregation and Causes Cell Death J. Biol. Chem., August 12, 2005; 280(32): 29096 - 29106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pickhardt, Z. Gazova, M. von Bergen, I. Khlistunova, Y. Wang, A. Hascher, E.-M. Mandelkow, J. Biernat, and E. Mandelkow Anthraquinones Inhibit Tau Aggregation and Dissolve Alzheimer's Paired Helical Filaments in Vitro and in Cells J. Biol. Chem., February 4, 2005; 280(5): 3628 - 3635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Halverson, J. Lewis, S. Frausto, M. Hutton, and N. A. Muma Tau Protein Is Cross-Linked by Transglutaminase in P301L Tau Transgenic Mice J. Neurosci., February 2, 2005; 25(5): 1226 - 1233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-H. Cho and G. V. W. Johnson Glycogen Synthase Kinase 3{beta} Induces Caspase-cleaved Tau Aggregation in Situ J. Biol. Chem., December 24, 2004; 279(52): 54716 - 54723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Krishnamurthy and G. V. W. Johnson Mutant (R406W) Human Tau Is Hyperphosphorylated and Does Not Efficiently Bind Microtubules in a Neuronal Cortical Cell Model J. Biol. Chem., February 27, 2004; 279(9): 7893 - 7900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. C. Tsai, P. S. Fishman, N. V. Thakor, and G. A. Oyler Parkin Facilitates the Elimination of Expanded Polyglutamine Proteins and Leads to Preservation of Proteasome Function J. Biol. Chem., June 6, 2003; 278(24): 22044 - 22055. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
